Brooklyn FI LLC Takes $244,000 Position in iShares Biotechnology ETF (NASDAQ:IBB)

Brooklyn FI LLC purchased a new position in iShares Biotechnology ETF (NASDAQ:IBB) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 1,694 shares of the financial services provider’s stock, valued at approximately $244,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in IBB. BNP Paribas Financial Markets grew its position in shares of iShares Biotechnology ETF by 29.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,380,229 shares of the financial services provider’s stock valued at $346,561,000 after acquiring an additional 538,899 shares during the period. Commerce Bank lifted its stake in iShares Biotechnology ETF by 1.8% in the third quarter. Commerce Bank now owns 743,366 shares of the financial services provider’s stock valued at $108,234,000 after purchasing an additional 12,921 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its holdings in iShares Biotechnology ETF by 32.9% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 663,000 shares of the financial services provider’s stock valued at $96,533,000 after purchasing an additional 164,000 shares during the period. Main Management ETF Advisors LLC increased its position in iShares Biotechnology ETF by 2.5% in the third quarter. Main Management ETF Advisors LLC now owns 593,370 shares of the financial services provider’s stock worth $86,395,000 after buying an additional 14,535 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of iShares Biotechnology ETF in the fourth quarter valued at $55,010,000. 62.45% of the stock is owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Stock Performance

IBB stock opened at $134.57 on Thursday. The stock has a fifty day moving average of $136.25 and a 200-day moving average of $139.54. iShares Biotechnology ETF has a fifty-two week low of $123.60 and a fifty-two week high of $150.57. The company has a market capitalization of $6.14 billion, a price-to-earnings ratio of 27.83 and a beta of 0.77.

iShares Biotechnology ETF Increases Dividend

The firm also recently disclosed a dividend, which will be paid on Friday, March 21st. Shareholders of record on Tuesday, March 18th will be issued a dividend of $0.1212 per share. The ex-dividend date of this dividend is Tuesday, March 18th. This is an increase from iShares Biotechnology ETF’s previous dividend of $0.06.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.